Navigation Links
Delcath Announces Completion of Regulatory Notification Process in New Zealand
Date:10/19/2011

liver cancers. The Company obtained authorization to affix a CE Mark for the Delcath Hepatic CHEMOSAT delivery system in April 2011. The Company has not yet received FDA approval for commercial sale of its system in the United States. For more information, please visit the Company's website at http://www.delcath.com/.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to commercialize the CHEMOSAT system in New Zealand including adoption, use and resulting sales, if any, regulatory approval of the CHEMOSAT system in Australia and other countries in the Pacific region, the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our a
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Announces Updated Efficacy Results From Phase 3 Trial of Chemosaturation for Melanoma Metastases in the Liver Presented at European Multidisciplinary Cancer Congress
2. Delcath to Present at the JMP Securities Healthcare Conference on September 28, 2011
3. Delcath Systems, Inc. Hosts Symposium on Chemosaturation at CIRSE Annual Meeting
4. Delcath Announces Top-Line Results From Metastatic Colorectal Cohort in Phase II Trial of Chemosaturation System
5. Delcath Announces Encouraging Top-Line Results From Hepatobiliary Cohort in Phase II Trial of Chemosaturation System
6. Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011
7. Delcath Systems to Report Second Quarter Progress Update and Conduct Conference Call
8. Delcath Systems, Inc. Announces the Completion of Common Stock Offering
9. Delcath Systems, Inc. Announces the Sale of 5,000,000 Shares of Common Stock
10. Delcath on Preliminary List of Additions to Russell Microcap® Index
11. Delcath to Present at the JMP Securities Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and ... lots of Fluzone ® (Influenza Vaccine) for the 2014-2015 ... Food and Drug Administration (FDA) for distribution. The lots were ... least 65 million doses of seasonal influenza vaccine manufactured by ... providers and pharmacies in August. The U.S. ...
(Date:7/22/2014)... , July 22, 2014 Galmed Pharmaceuticals Ltd. ... company focused on the development and commercialization of a ... and cholesterol gallstones, announced today that the U.S. Food ... New Drug, or IND, application.  Such clearance will permit ... aramchol, in the United States ...
(Date:7/22/2014)... 22, 2014  Neurotrope Bioscience, Inc., a subsidiary of ... license agreement with the Icahn School of Medicine at ... Sinai ) to utilize its proprietary information and ... treatment of Niemann-Pick Type C Disease (NPC), a rare ... symptoms. The license also covers other diseases and disorders ...
Breaking Medicine Technology:Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 3Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 5Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 6Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 7Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 2Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 3Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5
... Cara Therapeutics, Inc. announced today that it ... $15 million .  The round was led by new ... Biopharma, Ascent Biomedical Ventures, CT Innovations, Devon Park BioVentures, ... Science Partners. In conjunction with the financing, Martin ...
... July 20 Eli Lilly and Company (NYSE: ... of Alnara Pharmaceuticals, Inc., a privately-held company developing protein therapeutics for ... July 2, 2010 , has received the approval of Alnara stockholders ... conditions have also been met. , ...
Cached Medicine Technology:Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845 2Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845 3Lilly Announces Completion of Alnara Acquisition 2Lilly Announces Completion of Alnara Acquisition 3
(Date:7/22/2014)... (PRWEB) July 22, 2014 United Benefit ... organization, announces that Les McPhearson, an insurance veteran with ... CEO effective immediately and be based in the company's ... "I am delighted that Les chose to accept this ... qualified to address the many challenges facing UBA and ...
(Date:7/22/2014)... HealthDay Reporter TUESDAY, July 22, ... may be more likely to have children with asthma than ... compared with children born from mothers of normal weight, those ... to 20 to 30 percent higher odds of asthma," said ... at Children,s Hospital of Pittsburgh. Forno,s team also found ...
(Date:7/22/2014)... the Clean Plate Club you eat pretty much everything ... A new Cornell University study shows that the average adult ... or her plate. "If you put it on ... Ph.D., author of the forthcoming book, Slim by Design, Professor ... Lab. , Wansink and co-author Katherine Abowd Johnson analyzed 1179 ...
(Date:7/22/2014)... 22, 2014 Legislation backed by ... to Local Pharmacies Act of 2014”) championing so-called ... would undermine the availability of lower cost preferred ... billion over the next 10 years, according to ... the Pharmaceutical Care Management Association (PCMA). , The ...
(Date:7/22/2014)... New guidelines on cholesterol treatment and cardiovascular risk assessment ... of dying from atherosclerotic cardiovascular disease or of having ... a similar risk profile (based on age, smoking history, ... this finding for when and how aggressively to treat ... Journal of Men,s Health , a peer-reviewed publication from ...
Breaking Medicine News(10 mins):Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 3Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 4Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 5Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 2Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 3Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2
... ... addition to one of the most superior personalisation services in the industry. With an easy ... invite or thank you with their own words and photos and then order as many ... ...
... ... thing for your loved ones this holiday season, give them the gift of time by ... Delegate Source. , ... (PRWEB) December 12, 2009 -- Residents of the Denver and Boulder metro areas have the ...
... , Consumer Watchdog Calls For Preserving State Authority, ... WASHINGTON, Dec. 15 Consumer Watchdog condemned the removal of the ... from the U.S. Senate health reform bill. But the group said ... greatly weakened bill to prevent ceding the entire health care system ...
... , , ... , WASHINGTON, Dec. 15 Sen. Max Baucus has earned a ... and Nice List after being caught telling a brazen lie on the ... not raise taxes. , Speaking on the U.S. Senate floor on Nov. ...
... age were evaluated, Italian study found , TUESDAY, Dec. 14 ... fibrosis decreases when screening for potential parents who might be ... neonatal screening has been conducted in an area of northeast ... seen a significant progressive decline in the number of infants ...
... ... released some sobering statistics concerning the parallel rise in diabetes and obesity rates in the ... workforce. , ... December 14, 2009 -- Rates of diabetes are climbing across America due in large part ...
Cached Medicine News:Health News:The UK's Biggest Card Retailer Takes Choice and Value Personally 2Health News:The UK's Biggest Card Retailer Takes Choice and Value Personally 3Health News:The UK's Biggest Card Retailer Takes Choice and Value Personally 4Health News:Give the Gift of Service This Holiday Season with Delegate Source 2Health News:Give the Gift of Service This Holiday Season with Delegate Source 3Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 2Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 3Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 4Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 5Health News:ATR: Baucus Earns Place on 2009 "Naughty" List 2Health News:ATR: Baucus Earns Place on 2009 "Naughty" List 3Health News:Wider Adult Screening May Mean Fewer Children With Cystic Fibrosis 2Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 2Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 3
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
A straightforward, versatile approach to arthroscopically assisted pin placement in either the ankle or wrist....
... SureStep Drug Screen Tests are available in ... MDMA (Ecstasy). Designed using Microgenics Antibody Technology, ... only point of care immunoassay targeted to ... both MDA and MDEA but no cross-reactivity ...
Medicine Products: